Response
The Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) investigated the effects of candesartan cilexetil on exercise time and the signs and symptoms of congestive heart failure in patients with heart disease. The first patient was enrolled in January 1996 and the last case was completed in June 1997. The study was approved by a total of 52 independent ethical committees in Germany (nϭ17), the Czech Republic (nϭ34), and the Slovak Republic (nϭ1), and it fulfilled all regulatory requirements. All patients gave informed consent, as stated in the declaration of Helsinki. In addition, the informed consent form and patient information leaflet were approved by the ethical committees. In the patient information leaflet, it was stated that angiotensin-converting enzyme inhibitor treatment would be withdrawn and background medication with digoxin and diuretics would be optimized. The patients were randomized into 4 groups, 1 of which was placebo. At any time during the study, the patients and/or their physicians could stop the trial medication.
To avoid harm to patients, those with an ejection fraction Ͻ30% were excluded from the study. This was done on the basis of the results of the most important and most appropriate controlled trial, the Studies of Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure (SOLVD). 1 In this trial, the investigators analyzed predefined subgroups with respect to the end point death and the combined end point of death or hospitalization. They divided the baseline ejection fraction by terciles. No significant benefit in either end point was observed between ejection fractions of 30% and 35% during an average follow-up of 41.4 months. The restriction of the ejection fraction in our study, in fact, resulted in the recruitment of patients with a mean ejection fraction between 38.6% and 39.0%. This value is near the lower limit of a normal ejection fraction, as measured by echocardiography.
To avoid the inclusion of unstable patients in the trial after randomization, a relatively long wash-out/run-in phase was chosen. During this phase, the patients were seen every 2 weeks and could be excluded at any time and treated appropriately by their physician. If any problems arose for the patients, the same applied after randomization. The STRETCH study design was thoroughly reviewed by the ethical committees, and all possible safeguards were included. Furthermore, during the entire study period, the trial was scrutinized by an independent expert safety committee, which consisted of a cardiologist, statistician, and epidemiologist.
The STRETCH study had the confidence of all the relevant regulatory and ethics committees involved, was performed under the scrutiny of an independent expert safety committee, and was conducted using the highest standards. Therefore, we do not share the concerns of Drs Littmann and Stell.
